San Juan Mari Des J, Florencio Mary Queen V, Joven Mark Henry
AACE Clin Case Rep. 2020 Nov 23;6(6):e361-e364. doi: 10.4158/ACCR-2020-0524. eCollection 2020 Nov-Dec.
Subacute thyroiditis (SAT) is an inflammatory disorder of the thyroid gland that causes destructive thyrotoxicosis and is attributed to a viral or post-viral response. SARS-CoV-2 is a novel coronavirus that caused a global pandemic in 2020. We present a case that suggests that there may be a relationship between SAT and corona-virus disease 2019 (COVID-19).
We describe the clinical findings, thyroid function tests, and neck ultrasound of a patient presenting with anterior neck pain.
A 47-year-old, Filipino female presented with anterior neck pain associated with neck tenderness and goiter. She did not have fever or respiratory symptoms but had right lower lobe pneumonia on chest radiograph. Thyroid function tests were consistent with subclinical hyperthyroidism with thyroid-stimulating hormone of 0.05 μIU/mL (reference range is 0.47 to 4.68 μIU/mL), free thyroxine of 1.68 pg/mL (reference range is 0.78 to 2.19 pg/mL), and total triiodothyronine of 1.4 ng/mL (reference range is 0.97 to 1.69 ng/mL). Anti-thyroid peroxidase, anti-thyroglobulin, and thyroid-stimulating hormone receptor antibodies were negative. Neck ultrasound showed heterogenous thyroid tissues with normal vascularity. Reverse transcription-polymerase chain reaction for SARS-CoV-2 using nasopharyngeal and oropharyngeal swabs were positive. The patient was diagnosed as having SAT and was treated with mefenamic acid, which was later switched to celecoxib. Ceftriaxone and hydroxychloroquine were started for COVID-19 pneumonia. Complete resolution of symptoms and primary hypothyroidism occurred after 2 months.
SAT may be a presenting symptom or a sequela of COVID-19. Histopathology studies and definitive documentation of the virus in thyroid tissues may be required to confirm the relationship between SAT and COVID-19.
亚急性甲状腺炎(SAT)是一种甲状腺的炎症性疾病,可导致破坏性甲状腺毒症,其病因被认为是病毒感染或病毒感染后的反应。严重急性呼吸综合征冠状病毒2(SARS-CoV-2)是一种新型冠状病毒,于2020年引发了全球大流行。我们报告一例病例,提示SAT与2019冠状病毒病(COVID-19)之间可能存在关联。
我们描述了一名出现颈前疼痛患者的临床症状、甲状腺功能检查及颈部超声检查结果。
一名47岁的菲律宾女性,表现为颈前疼痛,伴有颈部压痛和甲状腺肿大。她没有发热或呼吸道症状,但胸部X线片显示右下叶肺炎。甲状腺功能检查结果符合亚临床甲状腺功能亢进,促甲状腺激素为0.05 μIU/mL(参考范围为0.47至4.68 μIU/mL),游离甲状腺素为1.68 pg/mL(参考范围为0.78至2.19 pg/mL),总三碘甲状腺原氨酸为1.4 ng/mL(参考范围为0.97至1.69 ng/mL)。抗甲状腺过氧化物酶、抗甲状腺球蛋白及促甲状腺激素受体抗体均为阴性。颈部超声显示甲状腺组织不均匀,血管正常。使用鼻咽拭子和口咽拭子进行的SARS-CoV-2逆转录聚合酶链反应呈阳性。该患者被诊断为SAT,并接受了甲芬那酸治疗,随后改用塞来昔布。针对COVID-19肺炎开始使用头孢曲松和羟氯喹。2个月后症状完全缓解,出现原发性甲状腺功能减退。
SAT可能是COVID-19的一种表现症状或后遗症。可能需要进行组织病理学研究及在甲状腺组织中明确检测到该病毒,以证实SAT与COVID-19之间的关系。